{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Acute"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Late"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Number of patients with grade 3-5 acute (start of treatment through 90 days from the completion of treatment) and late (after 90 days from the completion of treatment) adverse events, according to NCI's Common Terminology Criteria for Adverse Events (CTCAE) v4.0 toxicity criteria.","groups":[{"description":"All patients on the clinical trial.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"90 days, 3 years","title":"Number of Patients With Grade 3-5 Acute and Late Toxicities Following Treatment With SABR","type":"SECONDARY","unitOfMeasure":"participants"}